KR101961897B1 - Preparation method of sacylitol - Google Patents

Preparation method of sacylitol Download PDF

Info

Publication number
KR101961897B1
KR101961897B1 KR1020177023388A KR20177023388A KR101961897B1 KR 101961897 B1 KR101961897 B1 KR 101961897B1 KR 1020177023388 A KR1020177023388 A KR 1020177023388A KR 20177023388 A KR20177023388 A KR 20177023388A KR 101961897 B1 KR101961897 B1 KR 101961897B1
Authority
KR
South Korea
Prior art keywords
methyl
reaction
solvent
biphenol
temperature
Prior art date
Application number
KR1020177023388A
Other languages
Korean (ko)
Other versions
KR20170117091A (en
Inventor
쉬에농 쉬
Original Assignee
쑤저우 미라크파르마 테크놀로지 컴퍼니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 쑤저우 미라크파르마 테크놀로지 컴퍼니 리미티드 filed Critical 쑤저우 미라크파르마 테크놀로지 컴퍼니 리미티드
Publication of KR20170117091A publication Critical patent/KR20170117091A/en
Application granted granted Critical
Publication of KR101961897B1 publication Critical patent/KR101961897B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00Preparation of carboxylic acid amides
    • C07C231/02Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00Preparation of carboxylic acid amides
    • C07C231/22Separation; Purification; Stabilisation; Use of additives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/01Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/47Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)

Abstract

본 발명은 신형 혈압 강하약 LCZ696 성분 중의 하나인 사큐비톨(Sacubitril, AHU-377,I)의 제조방법에 관한 것으로서, 그 제조방법은 즉 비대칭유도시약 (S)-1-(α-아미노벤질)-2-나프탈레놀(S-betti Base)과 2R-메틸-4-옥소-부탄산의 고리화, 첨가, 탈벤질, 고리열기, 에스테르화 및 아미드화 반응 단계에 의해 사큐비톨(I)이 제조된다. 상기 제조방법은 원료가 쉽게 얻어지고, 공정이 간단하며, 경제적이고 친환경적이며, 산업화 생산에 아주 적합하다. The present invention relates to a process for the production of Sacubitril (AHU-377, I), one of the components of the new blood pressure lowering drug, LCZ696, which comprises the asymmetric induction reagent (S) -1- ) Cyclic addition, debenzylation, cyclization, esterification and amidation of 2-methyl-2-naphthalenol and 2R-methyl-4-oxo-butanoic acid ). The above production method is easy to obtain the raw material, simple in process, economical and environment-friendly, and is very suitable for industrial production.

Description

사큐비톨의 제조방법Preparation method of sacylitol

본 발명은 유기합성 노선 디자인 및 그 원료약과 중간체의 제조 분야에 관한 것으로서, 특히 네프릴라이신 억제제 사큐비톨(Sacubitril)의 제조방법에 관한 것이다. Field of the Invention The present invention relates to the field of organic synthesis route design and the production of its raw materials and intermediates, and in particular to a process for the preparation of the neprilyl lysine inhibitor Sacubitril.

LCZ696은 노바티스(Novartis) 회사로부터 개발된 신형 혈압강하제로서, 이 약품은 노바티브의 디오반(Diovan, 통칭: 발살탄)과 실험약 Sacubitril (AHU-377) 등 2가지 성분으로 구성되며, 그 중 발살탄은 혈관의 확장을 개선하고 인체의 나트륨과 물의 배출을 자극하며, Sacubitri은 혈압저하를 위협하는 2가지 멀티펩티드의 작용 메커니즘을 차단하므로, LCZ696은 안지오텐신Ⅱ수용체와 네프릴라신의 이중억제제로 불리우고 있다. 이 약품이 임상 상 나타내는 독특한 작용방식은 표준약품의 강압작용과 심장쇠약을 덜어주는 효능에 비해 우월하기에, 미국 FDA와 유럽연합 EMEA의 신속채널 평가자격을 취득하였다. 업계에서는 LCZ696이 전통적인 심장쇠약 치료방안의 혁신을 가져올 것이라고 보편적으로 인정하고 있다. Sacubitril (AHU-377)은 중국어로 번역된 표준명칭이 없으므로 본 출원자는 그 발음을 빌어 “사큐비톨”로 이름 지었다. LCZ696 is a new type of hypotensive agent developed by Novartis. It consists of two components: Novovib (Diovan) and Vasutan (Saccharide) (AHU-377) LCZ696 is referred to as a dual inhibitor of angiotensin II receptor and neprilasin, because it inhibits the mechanism of action of two multi-peptides that enhance blood vessel dilation and stimulate the release of sodium and water in the body and Sacubitri, which threatens blood pressure lowering . The unique clinical mode of action of this drug demonstrates superiority over standard drug efficacy and relieving heart failure, and has earned the US FDA and European EMEA fast channel evaluation qualifications. The industry has universally acknowledged that the LCZ696 will revolutionize traditional heart disease treatment options. Since Sacubitril (AHU-377) does not have a standardized name translated into Chinese, the applicant named it "Sakyubitol" by pronouncing it.

사큐비톨의 화학명은 4-(((2S,4R)-1-(1,1'-비페놀-4-일)-5-에톡시-4-메틸-5-옥소-펜탄-2-일)아미노)-4-옥소-부탄산(I), 그 구조식은 아래와 같고,The chemical name of sacylitol is 4 - (((2S, 4R) -1- (1,1'-biphenol-4-yl) -5-ethoxy- ) Amino) -4-oxo-butanoic acid (I), the structural formula of which is shown below,

Figure 112017081076857-pct00001
Figure 112017081076857-pct00001

사큐비톨의 제조방법에 대해서는 이미 많이 보도되어 있는바, 그 중 미국 특허 US5217996과 국제특허 WO2008031567, WO2010136474와 WO2012025501 등에는 아래 합성노선이 보도되어 있다. 비대칭 아미노 알코올을 원료로, 알데히드로 산화, 비티히반응, 비대칭 수소첨가 및 아미드화 축합 등 반응에 의해 목표산물이 제조된다. The production method of the saccharide has already been reported, and the following synthetic routes are reported in US Pat. No. 5,217,996 and International Patents WO2008031567, WO2010136474 and WO2012025501. Asymmetric amino alcohols are used as starting materials, and the desired products are produced by reactions such as oxidation with aldehydes, Bietih reaction, asymmetric hydrogenation, and amidation condensation.

Figure 112017081076857-pct00002
Figure 112017081076857-pct00002

또한, 국제특허 WO2008083967, WO2011088797, WO2012025502와 WO2014198195 등에는 다른 유형의 제조방법이 보도되어 있다. 이 노선은 2-카르보닐 프롤린을 원료로, 카르보닐 액티브화, 비페닐 치환, 카르보닐 환원, 비대칭 메틸화, 고리열기 반응 및 아미드화 축합 등 반응에 의해 목표산물이 제조된다. Other types of manufacturing methods are reported in International Patents WO2008083967, WO2011088797, WO2012025502 and WO2014198195. The target product is prepared by the reaction of 2-carbonylproline as a raw material with carbonyl activation, biphenyl substitution, carbonyl reduction, asymmetric methylation, cyclopentylation, and amidation condensation.

Figure 112017081076857-pct00003
Figure 112017081076857-pct00003

상기 2편의 문헌에 기재된 합성노선은 초기원료의 사용, 비대칭 형성방법 및 단원 반응의 순서가 다소 다르지만, 모두가 비대칭 원료를 얻기 힘들고, 반응절차가 많고, 비대칭 촉매화 환원 촉매제가 비싸며, 카르보닐 또는 아미노 보호와 탈보호를 반복하여 사용하는 등 결함을 갖고 있어, 상기 합성노선이 산업화를 실현함에 있어 애로사항으로 되고 있다. Although the synthesis routes described in the above two documents are somewhat different in the order of use of the starting raw materials, the asymmetric formation method and the unit reaction, all of them are difficult to obtain asymmetric raw materials, the reaction procedure is extensive, the asymmetric catalytic reduction catalyst is expensive, It has defects such as repeated use of amino protection and deprotection, which makes it difficult to realize industrialization of the synthetic route.

이로 볼 때, 기존 제조방안은 목표화합물의 비대칭 아미노기의 제조문제를 완전히 해결하지 못했으며, 기존공정은 원료, 원가, 설비 및 친환경 등 여러 방면의 제한을 받아, 산업화가 아주 어렵다. 때문에 현대 비대칭 합성기술을 어떻게 운용하고 비대칭 유도제를 어떻게 효과적으로 사용하며, 어떻게 간단하고 신속하고 경제적이며, 친환경 및 산업화가 용이한 새로운 합성노선을 설계 및 개발할 것인가에 대해 중요한 의의를 가진다. Thus, conventional manufacturing methods have not completely solved the problem of producing asymmetric amino groups of target compounds, and conventional processes are very difficult to industrialize due to various restrictions such as raw materials, cost, equipment, and environmental friendliness. It is therefore important to understand how to operate modern asymmetric synthesis techniques, how to effectively use asymmetric directing agents, and how to design and develop new synthetic routes that are simple, fast and economical, eco-friendly and easy to industrialize.

본 발명은 종래기술에 존재하는 결함에 대해, 얻기 쉬운 공업원료와 비대칭 유도제 “베티 베이스(Betti base)”로 목표산물 사큐비톨을 제조함을 목적으로 하는바, 이 방법은 원료가 쉽게 얻어지고 공정이 간단하며, 친환경 및 산업화 생산에 작합하는 등 장점을 가진다. The object of the present invention is to prepare the target product saccharide with a readily available industrial raw material and an asymmetric directing agent " Betti base " for defects present in the prior art, It has advantages such as simple process, environment friendly and industrial production.

상기 발명의 목적을 구현하고자 본 발명은 아래의 주요 기술방안을 채용하는데, 네프릴라이신 억제제 사큐비톨(Sacubitri,Ⅰ)의 제조 방법에 있어서, In order to achieve the object of the present invention, the present invention adopts the following main technical solution, which is a method for producing the neprilysin inhibitor Sacubitri (I)

Figure 112017081076857-pct00004
Figure 112017081076857-pct00004

그 제조방법은 (S)-1-(α-아미노벤질)-2-나프탈레놀(Ⅱ)과 2R-메틸-4-옥소-부탄산(Ⅲ)의 고리화반응에 의해, (7aR,9R,12S)-9-메틸-10-옥소-12-페닐-7a,8,9,10-테트라히드로-12H-나프토[1,2-e]피롤환[2,1-b][1,3]옥사진(Ⅳ)을 생성하고, 상기 (7aR,9R,12S)-9-메틸-10-옥소-12-페닐-7a,8,9,10-테트라히드로-12H-나프토[1,2-e]피롤환[2,1-b][1,3]옥사진(Ⅳ)은 (1,1'-비페닐-4-메틸) 염화 마그네슘 또는 (1,1'-비페닐-4-메틸) 브롬화 마그네슘 등 그리나드 시약과의 첨가반응에 의해, (1S,3R,5S)-1-[[3-메틸-5-(1,1'-비페닐-4-일-메틸)-2-피롤리돈]벤질]-2-나프탈레놀(Ⅴ)을 생성하며, 상기 (1S,3R,5S)-1-[[3-메틸-5-(1,1'-비페닐-4-일-메틸)-2-피롤리돈]벤질]-2-나프탈레놀(Ⅴ)은 탈벤질 반응을 거쳐, (3R,5S)-3-메틸-5-(1,1'-비페놀-4-일-메틸)-2-피롤리돈(Ⅵ)을 생성하고, 상기 (3R,5S)-3-메틸-5-(1,1'-비페놀-4-일-메틸)-2-피롤리돈(Ⅵ)은 산성촉매의 작용하에서 에탄올 중에서 고리열기 및 에스테르화 반응에 의해, (2R,4S)-2-메틸-4-아미노-5-(1,1'-비페놀-4-일)-발레르산에틸(Ⅶ)을 얻으며, 상기 (2R,4S)-2-메틸-4-아미노-5-(1,1'-비페놀-4-일)-발레르산에틸(Ⅶ)과 호박산무수물은 알칼리성 촉진제의 작용하에서, 아미드화 반응을 일으켜 사큐비톨(Ⅰ)이 얻어지는 단계를 포함한다. (7aR, 9R) by the cyclization reaction of (S) -1- (alpha -aminobenzyl) -2-naphthalenol (II) with 2R-methyl-4-oxo-butanoic acid , 12S) -9-methyl-10-oxo-12-phenyl-7a, 8,9,10-tetrahydro-12H-naphtho [ 3] oxazine (IV), and reacting the (7aR, 9R, 12S) -9-methyl-10-oxo-12- Biphenyl-4-methyl) magnesium chloride or (1,1'-biphenyl-4-methyl) -Methyl) -5-bromo-5-methyl-5-methyl-5- (1,1'-biphenyl- (3-methyl-5- (1,1'-biphenyl-4-yl) (3R, 5S) -3-methyl-5- (1,1'-biphenol (3R, 5S) -3-methyl-5- (1,1'-biphenol-4-yl-methyl) -2 - pyrrolidone (VI) (1,1'-biphenol-4-yl) -valerate ((2R, 4S) -2-methyl-4-amino- (VII) and succinic anhydride are reacted with an alkaline promoting agent (VIII), and the (2R, 4S) -2-methyl- , An amidation reaction is carried out to obtain the cubitol (I).

Figure 112017081076857-pct00005
Figure 112017081076857-pct00005

또한, 본 발명은 아래 부속 기술수단을 제시하였다. The present invention also provides the following technical means.

상기 (S)-1-(α-아미노벤질)-2-나프탈레놀(Ⅱ)과 2R-메틸-4-옥소-부탄산(Ⅲ)의 고리화반응의 원료투여 몰비는 1:1~2이고, 바람직하게는 1:1.0~1.3으로 하며, 상기 고리화반응의 용매는 톨루엔, 1,2-디클로로 에탄, N,N-디메틸포름아미드, 아세토니트릴 또는 디메틸설폭시드이고, 바람직하게는 톨루엔으로 하며, 상기 고리화반응 온도는 25~100℃이고, 바람직하게는 55~70℃로 한다. The starting molar ratio of the cyclization of (S) -1- (α-aminobenzyl) -2-naphthalenol (II) and 2R-methyl-4-oxo-butanoic acid (III) Preferably 1: 1.0 to 1.3, and the solvent of the cyclization reaction is toluene, 1,2-dichloroethane, N, N-dimethylformamide, acetonitrile or dimethylsulfoxide, preferably toluene And the cyclization reaction temperature is 25 to 100 ° C, preferably 55 to 70 ° C.

상기 (7aR,9R,12S)-9-메틸-10-옥소-12-페닐-7a,8,9,10-테트라히드로-12H-나프토[1,2-e]피롤환[2,1-b][1,3]옥사진(Ⅳ)과 (1,1'-비페닐-4-메틸) 염화 마그네슘 또는 (1,1'-비페닐-4-메틸) 브롬화 마그네슘 등 그리나드 시약의 첨가반응의 원료투여 몰비는 1:1-2이고, 바람직하게는 1:1.2~1.6이며, 상기 첨가반응의 용매는 에틸에테르, 이소프로필에테르, 테트라히드로푸란 또는 2-메틸테트라히드로푸란이고, 바람직하게는 에틸에테르 또는 테트라히드로푸란으로 하며, 상기 첨가반응 온도는 -100~0℃이고, 바람직하게는 -78℃로 한다. (7aR, 9R, 12S) -9-methyl-10-oxo-12-phenyl-7a, 8,9,10-tetrahydro- 12H-naphtho [ (1, 1'-biphenyl-4-methyl) magnesium chloride or (1,1'-biphenyl-4-methyl) The raw material dosing molar ratio of the reaction is 1: 1-2, preferably 1: 1.2-1.6, and the solvent for the addition reaction is ethyl ether, isopropyl ether, tetrahydrofuran or 2-methyltetrahydrofuran, Is ethyl ether or tetrahydrofuran, and the addition reaction temperature is -100 to 0 占 폚, preferably -78 占 폚.

상기 탈벤젠 반응의 반응 체계는 Pd/C 촉매 수소첨가 환원체계 또는 세륨함유 질산 암모늄 산화 체계이다. 상기 Pd/C 촉매 수소첨가 환원체계의 용매는 메탄올, 에탄올, 이소 프로판올, 디클로로메탄, 초산에틸 또는 이소 프로필 아세테이트이고, 바람직하게는 메탄올로 한다. 상기 세륨함유 질산 암모늄 산화체계의 용매는 아세토니트릴/물, 디클로로 메탄/물 또는 테트라히드로푸란/물이고, 바람직하게는 아세토니트릴/물이고, 그 체적비는 1-5:1이고, 바람직하게는 2:1로한다. The reaction system of the debenzene reaction is a Pd / C catalytic hydrogenation reduction system or a cerium containing ammonium nitrate oxidation system. The solvent of the Pd / C catalytic hydrogenation reduction system is methanol, ethanol, isopropanol, dichloromethane, ethyl acetate or isopropyl acetate, preferably methanol. The solvent of the cerium containing ammonium nitrate system is acetonitrile / water, dichloromethane / water or tetrahydrofuran / water, preferably acetonitrile / water, the volume ratio is 1-5: 1, preferably 2 : 1.

상기 고리열기 및 에스테르화 반응의 산성촉매는 염산, 유산, 트리플루오로아세트산, 과염소산 또는 p-술폰산 톨루엔이고, 바람직하게는 염산 또는 유산이며, 상기 고리열기 및 에스테르화 반응의 용매는 에탄올로 하며, 상기 고리열기 및 에스테르화 반응의 온도는 0~100℃이고, 바람직하게는 70~90℃로 한다.The acidic catalyst for the ring opening and esterification reaction is hydrochloric acid, sulfuric acid, trifluoroacetic acid, perchloric acid or p-sulfonic acid toluene, preferably hydrochloric acid or sulfuric acid, the solvent for the cyclic thermal and esterification reaction is ethanol, The temperature of the cyclization and esterification reaction is 0 to 100 캜, preferably 70 to 90 캜.

상기 아미드화 반응의 알칼리 촉진제는 수산화마트륨, 탄산칼륨, 탄산나트륨, tert-부틸알코올, 피리딘 또는 트리에틸아민이고, 바람직하게는 피리딘 또는 트리에틸아민으로 한다. 상기 아미드화 반응의 용매는 디클로로메탄, 테트라히드로푸란, 아세토니트릴, N,N-디메틸포름아미드 또는 디옥산이고, 바람직하게는 디클로로메탄 또는 테트라히드로푸란으로 하며, 상기 아미드화 반응 온도는 0~90℃이고, 바람직하게는 30~50℃로 한다. The alkali promoter for the amidation reaction is selected from the group consisting of sodium hydroxide, potassium carbonate, sodium carbonate, tert-butyl alcohol, pyridine or triethylamine, preferably pyridine or triethylamine. The amidation reaction temperature is preferably 0 to 90 ° C. The amidation reaction may be carried out in a solvent selected from the group consisting of dichloromethane, tetrahydrofuran, acetonitrile, N, N-dimethylformamide or dioxane, preferably dichloromethane or tetrahydrofuran, Deg.] C, preferably 30 to 50 [deg.] C.

종래기술에 비해, 본 발명에 관련되는 사큐비톨(I)의 제조방법은 원료가 쉽게 얻어지고, 공정이 간단하며, 친환경적이고 경제적인 등의 장점을 가지므로, 이 원료약의 산업화 생산에 유리하며, 그 경제기술의 발전을 촉진한다. Compared with the prior art, the production method of the saccharide (I) according to the present invention is advantageous in industrial production of the raw material drug because it has the advantages of easy obtaining of raw material, simple process, environment-friendly and economical And promote the development of economic technology.

아래에는 여러 가지 비교적 적합한 실시예에 결합하여, 본 기술수단에 대해, 더 한층 비제한성에 대해 상세하게 설명하기로 한다. 그중 원료 (S)-1-(α-아미노벤질)-2-나프탈레놀(Ⅱ)의 제조는 중국 발명특허 제 CN1348952A 호를 테마로 하는 “비대칭화합물(S)-(+)과 (R)-(-)-1-(α-아미노벤질젠)-2-나프탈레놀의 제조방법”의 해당 화합물 제조방법에 대한 설명(공개일자: 2002년 5월 15일)을 참조하며, 원료 2R-메틸-4-옥소-부탄산(Ⅲ)은 “Journal of the American Chemical Society, 107(2), 443-8; 1985”, “Journal of the American Chemical Society, 126(45), 14740-14745; 2004”과 “Tetrahedron, 63(26), 5754-5767; 2007” 등 문헌중과 같은 화합물의 제조방법을 참조한다. In the following, in combination with various comparatively preferred embodiments, further description of the non-limiting aspects of the present technical means will be given. The production of (S) -1- (α-aminobenzyl) -2-naphthalenol (Ⅱ) as a starting material was carried out in accordance with "Asymmetric compound (S) - (+) and (R)" under the theme of Chinese invention patent No. CN1348952A - (-) - 1- (α-aminobenzylen) -2-naphthalenol "(publication date: May 15, 2002), the raw material 2R- Methyl-4-oxo-butanoic acid (III) is described in Journal of the American Chemical Society, 107 (2), 443-8; 1985 ", " Journal of the American Chemical Society, 126 (45), 14740-14745; 2004 " and " Tetrahedron, 63 (26), 5754-5767; 2007 " and the like.

실시예 1Example 1

0-5℃와 질소 분위기하에서, (4S,1’R)-4,5-디히드로-2-(1-메틸-3-부틸렌)-4-(1-메틸에틸)옥사진(16.7g, 0.1mol)을 염산(10%w/w, 250mL)중에 넣고, 물이 끓을 때까지 온도를 높여, 교반하면서 3시간 반응시키고, 실온까지 냉각시키고, 디클로로메탄으로 3번 추출하며, 상압에서 용매를 회수하고, 압력을 감소하여 증류시켜, 황색의 액체 2R-메틸-4-펜텐산을 얻는다. 황색의 오일모양 물질을 250mL 디클로로베탄중에 넣고, 온도를 -78℃까지 내려, 오존을 통과시켜, 용액의 색갈이 점차 심녹색으로 변하게 하고, 약15분후에 반응을 종료시킨다. 질소로 여분의 오존을 제거하고 온도를 실온에로 높혀, 순차적으로 5%의 티오황산나트륨수용액과 순수한 물로 세척하고, 무수 황산나트륨으로 건조시키며, 용매를 회수하여 담황색의 오일모양 물질 2R-메틸-4-옥소-부탄산(Ⅲ) 7.9g을 얻는바, 그 수율은 68.1%이다. FAB-MS m/z: 117[M+H]+.(4S, 1'R) -4,5-dihydro-2- (1-methyl-3-butylene) -4- (1-methylethyl) oxazine (16.7 g , 0.1 mol) was added to hydrochloric acid (10% w / w, 250 mL), the temperature was raised until the water was boiled, the reaction was carried out for 3 hours with stirring, cooled to room temperature, extracted three times with dichloromethane, Is recovered and the pressure is reduced and distilled to obtain yellow liquid 2R-methyl-4-pentenoic acid. The yellow oily substance is placed in 250 mL of dichlorobetane, the temperature is lowered to -78 DEG C, the ozone is passed through, the color of the solution gradually changes to the heart-green color, and the reaction is terminated after about 15 minutes. The excess ozone was removed with nitrogen and the temperature was raised to room temperature. The solution was washed successively with 5% aqueous sodium thiosulfate solution and pure water, dried over anhydrous sodium sulfate, and the solvent was recovered to obtain a pale yellow oily substance 2R- 7.9 g of oxo-butanoic acid (III) was obtained, and the yield was 68.1%. FAB-MS m / z: 117 [M + H] < + >.

실시예 2Example 2

반응병 안에 (S)-1-(α-아미노벤질)-2-나프탈레놀(Ⅱ) (7.5g, 30mmol), 2R-메틸-4-옥소-부탄산(Ⅲ)(3.7g, 31.5mmol)과 톨루엔 100mL를 넣어, 온도를 40~50℃로 높혀, 교반하면서 36시간 반응시키고, TLC로 반응의 완료를 검측한다. 온도를 낮추어, 불용해물을 여과시켜 제거하며, 진공 건조에 의해 백색의 고체 (7aR,9R,12S)-9-메틸-10-옥소-12-페닐-7a,8,9,10-테트라히드로-12H-나프토[1,2-e]피롤환[2,1-b][1,3]옥사진(Ⅳ) 7.2g을 얻는바, 그 수율은 72.9%이다. 1H NMR (CDCl3) δ 7.72-765(m, 2H), 7.35-7.28(m, 1H), 7.24-7.13(m, 7H), 7.10(d, 1H), 5.84(s, 1H), 5.65-5.54(m, 1H), 2,43-2.67(m, 1H), 2.24-2.57(m, 2H), 1.16(d, 3H);FAB-MS m/z: 330[M+H]+.(7.5 g, 30 mmol) and 2R-methyl-4-oxo-butanoic acid (III) (3.7 g, 31.5 mmol ) And 100 mL of toluene were charged, and the temperature was raised to 40 to 50 DEG C, and the reaction was carried out for 36 hours with stirring, and the completion of the reaction was checked by TLC. The temperature was lowered to remove insoluble material by filtration and vacuum drying gave a white solid (7aR, 9R, 12S) -9-methyl-10-oxo-12-phenyl-7a, 8,9,10-tetrahydro- 7.2 g of 12H-naphtho [1,2-e] pyrrole [2,1-b] [1,3] oxazine (IV) was obtained. The yield was 72.9%. 1H NMR (CDCl 3) δ 7.72-765 (m, 2H), 7.35-7.28 (m, 1H), 7.24-7.13 (m, 7H), 7.10 (d, 1H), 5.84 (s, 1H), 5.65- FAB-MS m / z: 330 [M + H] < + >.

실시예 3Example 3

실온 및 질소 분위기하에서, 건조한 반응병 안에 소량의 브로모에탄(유발제), 마그네슘 파우더(1.0g, 40mmol) 및 건조한 테트라히드로푸란 10mL 넣고, 응을 유발시킨 후, 4-브로모메틸-1,1’-비페놀(4.92g, 20mmol)의 100mL 건조한 테트라히드로푸란 용액을 떨어뜨려 놓고, 그 후 계속하여 교반하면서 3~4시간 반응시켜, 그리나드 시약 (1,1'-비페놀-4-일-메틸) 브롬화 마그네슘을 얻는다. 온도를 -78℃로 내리고 (7aR,9R,12S)-9-메틸-10-옥소-12-페닐-7a,8,9,10-테트라히드로-12H-나프토[1,2-e]피롤환[2,1-b][1,3]옥사진(Ⅳ) (4.9g, 15mmol)의 100mL 건조한 테트라히드로푸란 용액을 떨어뜨려 놓고, 그 온도하에서 2~3시간 반응시키고, TLC로 반응의 완료를 검측한다. 포화염화암모늄 50mL로 반응을 끄고, 온도를 실온으로 높이며, 디클로로메탄으로 3번 추출하여, 유기상을 합병시키고 무수 황산마그네슘으로 건조시킨다. 농축후 잔류물을 초산에틸과 노멀헥산(체적비 1:1)로 재결정시켜, 백색의 고체 (1S,3R,5S)-1-[[3-메틸-5-(1,1'-비페닐-4-일-메틸)-2-피롤리돈]벤질]-2-나프탈레놀(Ⅴ) 6.4g을 얻는바, 그 수율은 85.8%이다. m.p. 215℃(분해),FAB-MS m/z: 498[M+H]+.A small amount of bromoethane (inducing agent), magnesium powder (1.0 g, 40 mmol), and dried tetrahydrofuran (10 mL) were placed in a dry reaction bottle at room temperature and under a nitrogen atmosphere, and 4-bromomethyl- '-Biphenol (4.92 g, 20 mmol) in tetrahydrofuran was dropped and then reacted for 3 to 4 hours with continued stirring to obtain a Grignard reagent (1,1'-biphenol-4-yl -Methyl) < / RTI > magnesium bromide. The temperature was lowered to -78 < 0 > C and a solution of (7aR, 9R, 12S) -9-methyl-10-oxo-12-phenyl-7a, 8,9,10-tetrahydro-12H-naphtho [ (100 ml) of tetrahydrofuran [2,1-b] [1,3] oxazine (IV) (4.9 g, 15 mmol) was dropped and reacted for 2 to 3 hours at that temperature. Completion is checked. The reaction was turned off with 50 mL of saturated ammonium chloride, the temperature was raised to room temperature, extracted three times with dichloromethane, the organic phase was combined and dried over anhydrous magnesium sulfate. After concentration, the residue was recrystallized from ethyl acetate and normal hexane (volume ratio 1: 1) to obtain a white solid (1S, 3R, 5S) -1 - [[3-methyl-5- (1,1'- Yl) methyl) -2-pyrrolidone] benzyl] -2-naphthalenol (V) was obtained in a yield of 85.8%. mp 215 [deg.] C (decomposition), FAB-MS m / z: 498 [M + H] < + >.

실시예 4Example 4

반응병 안에 (1S,3R,5S)-1-[[3-메틸-5-(1,1'-비페닐-4-일-메틸)-2-피롤리돈]벤질]-2-나프탈레놀(Ⅴ) (1.5g, 3mmol), 10% Pd/C (0.32g, 0.3mmol) 및 메탄올 25mL을 넣고, 실온 및 상압 하에서 수소가 흡수되지 않을 때까지 수소를 통과시킨 후 수소통과를 정지시킨다. 촉매제를 여과하여 회수하고, 압력을 내려 용매를 회수하며, 잔여물을 초산에틸과 노멀헥산(체적비 1:1)으로 재결정시켜, 백색 고체 (3R,5S)-3-메틸-5-(1,1'-비페놀-4-일-메틸)-2-피롤리돈(Ⅵ) 0.7g을 얻는바, 그 수율은 88.0%이다. 1H NMR (CDCl3) δ 7.54-7.58(m, 4H), 7.44(d, 2H), 7.33(m, 1H), 7.25(d, 2H), 7.13(s, 1H), 3.86 (m, 1H), 2.82(dd, 2H), 2.42(m, 1H), 1.83-2.13(m, 2H), 1.09(d, 3H);FAB-MS m/z: 266[M+H]+.The reaction was carried out by adding (1S, 3R, 5S) -1 - [[3-methyl-5- (1,1'-biphenyl-4-ylmethyl) -2- pyrrolidol] benzyl] Hydrogen was passed until hydrogen was not absorbed at room temperature and atmospheric pressure, and hydrogen passage was stopped. The reaction solution was cooled to room temperature and atmospheric pressure, . The catalyst was filtered off and the pressure was reduced to recover the solvent and the residue was recrystallized from ethyl acetate and normal hexane (volume ratio 1: 1) to give (3R, 5S) 1'-biphenol-4-yl-methyl) -2-pyrrolidone (VI) was obtained in a yield of 88.0%. 1H NMR (CDCl 3) δ 7.54-7.58 (m, 4H), 7.44 (d, 2H), 7.33 (m, 1H), 7.25 (d, 2H), 7.13 (s, 1H), 3.86 (m, 1H) , 2.82 (dd, 2H), 2.42 (m, 1H), 1.83-2.13 (m, 2H), 1.09 (d, 3H); FAB-MS m / z: 266 [M + H] + .

실시예 5Example 5

반응병 안에 (1S,3R,5S)-1-[[3-메틸-5-(1,1'-비페닐-4-일-메틸)-2-피롤리돈]벤질]-2-나프탈레놀(Ⅴ) (1.5g, 3mmol), 세륨함유 질산암모늄 (4.1g, 7.5mmol) 및 아세토니트릴과 물(체적비 2:1)의 혼합용매 55mL를 넣어, 실온하에서 5~7시간 교반시키며, TLC로 반응의 완료를 검측한다. 여과시키고, 여과액에 중탄산 나트륨 용액을 넣어, 디클로로에탄으로 3번 추출하고, 유기상을 합병하여 무수 탄산나트륨으로 건조시킨다. 압력을 낮추어, 농축시키고, 잔여물을 초산에틸과 노멀헥산(체적비1:1)으로 재결정시켜, 백색의 고체 (3R,5S)-3-메틸-5-(1,1'-비페놀-4-일-메틸)-2-피롤리돈(Ⅵ) 0.65g을 얻는바, 그 수율은 81.8%이다. 1H NMR (CDCl3) δ 7.54-7.58(m, 4H), 7.44(d, 2H), 7.33(m, 1H), 7.25(d, 2H), 7.13(s, 1H), 3.86(m, 1H), 2.82(dd, 2H), 2.42(m, 1H), 1.83-2.13(m, 2H), 1.09(d, 3H);FAB-MSm/z: 266[M+H]+.The reaction was carried out by adding (1S, 3R, 5S) -1 - [[3-methyl-5- (1,1'-biphenyl-4-ylmethyl) -2- pyrrolidol] benzyl] 55 mL of a mixed solvent of acetonitrile and water (volume ratio 2: 1) was added to the mixture, and the mixture was stirred for 5 to 7 hours at room temperature. To complete the reaction. Filter, add sodium bicarbonate solution to the filtrate, extract 3 times with dichloroethane, combine the organic phase and dry with anhydrous sodium carbonate. The filtrate was concentrated under reduced pressure and the residue was recrystallized from ethyl acetate and normal hexane (volume ratio 1: 1) to give white solid (3R, 5S) -3-methyl-5- (1,1'- Yl-methyl) -2-pyrrolidone (VI) was obtained in a yield of 81.8%. 1H NMR (CDCl 3) δ 7.54-7.58 (m, 4H), 7.44 (d, 2H), 7.33 (m, 1H), 7.25 (d, 2H), 7.13 (s, 1H), 3.86 (m, 1H) , 2.82 (dd, 2H), 2.42 (m, 1H), 1.83-2.13 (m, 2H), 1.09 (d, 3H); FAB-MS m / z: 266 [M + H] + .

실시예 6Example 6

반응병 안에 (3R,5S)-3-메틸-5-(1,1'-비페놀-4-일-메틸)-2-피롤리돈(Ⅵ) (1.33g, 5mmol), 36.5% 농염산 2mL 및 에탄올 25mL를 넣고, 교반하여 용해시킨 후, 온도를 75~85℃로 높혀, 24시간 교반하여, TLC로 반응의 완료를 검측한다. 압력을 낮추어 농축시키고, 잔여물을 디톨루엔으로 재결정시켜, 백색의 고체 (2R,4S)-2-메틸-4-아미노-5-(1,1'-비페놀-4-일)-발레르산에틸(Ⅶ) (염상염) 1.4g을 얻는바, 그 수율은 80.5%이다. 1H NMR (DMSO-d 6 ) δ 8.30(brs, 3H), 7.62(m, 4H), 7.43(m, 2H), 7.35(m, 2H), 7.31(m, 1H), 3.95(q, 2H), 3.36(m, 1H), 2.81-3.08(dd, 2H), 2.74(m, 1H), 1.85(m, 1H), 1.61(m, 1H), 1.08(t, 3H), 1.05(d, 3H);FAB-MS m/z: 312[M+H]+.(1.33 g, 5 mmol), 36.5% concentrated hydrochloric acid (1 ml) was added to the reaction bottle, to which was added a solution of (3R, 5S) -3-methyl- And 25 mL of ethanol are added and dissolved by stirring. The temperature is raised to 75 to 85 캜, and the mixture is stirred for 24 hours, and the completion of the reaction is checked by TLC. The filtrate was concentrated under reduced pressure and the residue was recrystallized from di-toluene to give white solid (2R, 4S) -2-methyl-4-amino-5- (1,1'-biphenol- 1.4 g of ethyl (VII) (salt salt) was obtained, and the yield was 80.5%. 1H NMR (DMSO- d 6) δ 8.30 (brs, 3H), 7.62 (m, 4H), 7.43 (m, 2H), 7.35 (m, 2H), 7.31 (m, 1H), 3.95 (q, 2H) 1H), 1.08 (t, 3H), 1.05 (d, 3H), 3.65 (m, ); FAB-MS m / z: 312 [M + H] < + >.

실시예 7Example 7

반응병 안에 (3R,5S)-3-메틸-5-(1,1'-비페놀-4-일-메틸)-2-피롤리돈(Ⅵ) (1.33g, 5mmol), 98% 농유산 1mL 및 에탄올 25mL를 넣고, 교반하여 용해시킨 후, 온도를 75~85℃로 높혀, 16시간 교반하여, TLC로 반응의 완료를 검측한다. 압력을 낮추어 농축시키고, 잔여물을 디톨루엔으로 재결정시켜, 백색의 고체 (2R,4S)-2-메틸-4-아미노-5-(1,1'-비페놀-4-일)-발레르산에틸(Ⅶ) (유산수소염) 1.8g을 얻는 바, 그 수율은 88.2%이다. 1H NMR (DMSO-d 6 ) δ 8.57(brs, 3H), 7.64(m, 4H), 7.46(m, 2H), 7.34(m, 2H), 7.33(m, 1H), 3.75(m, 2H), 2.78-2.98(dd, 2H), 2.66(m, 1H), 1.86(m, 1H), 1.58(m, 1H), 1.10-1.15(m, 6H);FAB-MS m/z: 312[M+H]+.The reaction mixture was charged with (3R, 5S) -3-methyl-5- (1,1'-biphenol-4-ylmethyl) -2- pyrrolidone (VI) And 25 mL of ethanol are added and dissolved by stirring, and then the temperature is raised to 75 to 85 DEG C and stirred for 16 hours, and the completion of the reaction is checked by TLC. The filtrate was concentrated under reduced pressure and the residue was recrystallized from di-toluene to give white solid (2R, 4S) -2-methyl-4-amino-5- (1,1'-biphenol- 1.8 g of ethyl (VII) (hydrogencarbonate) was obtained, and the yield was 88.2%. 1H NMR (DMSO- d 6) δ 8.57 (brs, 3H), 7.64 (m, 4H), 7.46 (m, 2H), 7.34 (m, 2H), 7.33 (m, 1H), 3.75 (m, 2H) , 2.78 (m, 1H), 2.86 (m, 1H), 1.86 (m, 1H) + H] + .

실시예 8 Example 8

반응병 안에 (2R,4S)-2-메틸-4-아미노-5-(1,1'-비페놀-4-일)-발레르산에틸(Ⅶ) (1.55g, 5mmol), 피리딘(1.2g, 15mmol) 및 디클로로메탄 25mL를 넣고, 교반하여 용해시킨 후, 숙신산 무수물(1.0g, 10mmol) 을 넣고, 온도를 40~45℃로 높혀, 교반하면서 6시간 반응시키며, 숙신산 무수물(0.5g, 5mmol) 추가하고, 계속하여 4시간 반응시켜, TLC로 반응의 완료를 검측한다. 압력을 낮추어, 농축시키고, 잔여물을 초산에틸과 노멀헥산으로 재결정시켜, 백색의 고체 사큐비톨(I) 1.6g을 얻는바, 그 수율은 77.9%이다. 1H NMR (CDCl3) δ 7.51(d, 2H), 7.46(d, 2H), 7.36(m, 2H), 7.27(m, 1H), 7.17(d, 2H), 5.72(d, 1H), 4.19(brs, 1H), 4.06(q, 2H), 2.87-2.72(m, 2H), 2.62-2.54(m, 2H), 2.49(brs, 1H), 2.43-2.33(m, 2H), 1.88(m. 1H), 1.54-1.43(m, 1H), 1.18(t, 3H), 1.10(d, 3H);FAB-MS m/z: 412[M+H]+.The reaction mixture was added with ethyl (VII) (1.55 g, 5 mmol), pyridine (1.2 g, 5 mmol), (2R, 4S) , Succinic anhydride (1.0 g, 10 mmol) was added, and the temperature was raised to 40 to 45 ° C. The mixture was reacted for 6 hours with stirring, and succinic anhydride (0.5 g, 5 mmol ), The reaction was continued for 4 hours, and the completion of the reaction was checked by TLC. The pressure was lowered and concentrated, and the residue was recrystallized from ethyl acetate and normal hexane to obtain 1.6 g of white solid cubicolide (I). The yield was 77.9%. 1H NMR (CDCl 3) δ 7.51 (d, 2H), 7.46 (d, 2H), 7.36 (m, 2H), 7.27 (m, 1H), 7.17 (d, 2H), 5.72 (d, 1H), 4.19 (brs, IH), 4.06 (q, 2H), 2.87-2.72 (m, 2H), 2.62-2.54 (M, 1H), 1.54-1.43 (m, 1H), 1.18 (t, 3H), 1.10 (d, 3H); FAB-MS m / z: 412 [M + H] + .

지적하여 둘 것은 상기 실시예는 단지 본 발명의 기술적 구상과 특징을 설명하기 위한 것으로서, 이 방면의 기술에 익숙한 기술자들로 하여금 본 발명의 내용을 이해하고, 이에 따라 실시하게 하며, 이를 이용하여 본 발명의 보호범위를 제한해서는 안 된다. 본 발명의 정신과 내용에 근거한 등가의 변화 또는 수정은 모두 본 발명의 보호범위 내에 속한다. It should be noted that the above embodiments are merely intended to illustrate the technical concept and features of the present invention and are intended to enable the skilled artisan skilled in the art to understand and to practice the present invention, The scope of protection of the invention shall not be limited. All equivalent changes or modifications based on the spirit and contents of the present invention are within the scope of the present invention.

Claims (6)

Figure 112017081076857-pct00006

(S)-1-(α-아미노벤질)-2-나프탈레놀과 2R-메틸-4-옥소-부탄산의 고리화반응에 의해, (7aR,9R,12S)-9-메틸-10-옥소-12-페닐-7a,8,9,10-테트라히드로-12H-나프토[1,2-e]피롤환[2,1-b][1,3]옥사진을 생성하고, 상기 (7aR,9R,12S)-9-메틸-10-옥소-12-페닐-7a,8,9,10-테트라히드로-12H-나프토[1,2-e]피롤환[2,1-b][1,3]옥사진은 (1,1'-비페닐-4-메틸) 염화 마그네슘 또는 (1,1'-비페닐-4-메틸) 브롬화 마그네슘과의 첨가반응에 의해, (1S,3R,5S)-1-[[3-메틸-5-(1,1'-비페닐-4-일-메틸)-2-피롤리돈]벤질]-2-나프탈레놀을 생성하며, 상기 (1S,3R,5S)-1-[[3-메틸-5-(1,1'-비페닐-4-일-메틸)-2-피롤리돈]벤질]-2-나프탈레놀은 탈벤질 반응을 거쳐, (3R,5S)-3-메틸-5-(1,1'-비페놀-4-일-메틸)-2-피롤리돈을 생성하고, 상기 (3R,5S)-3-메틸-5-(1,1'-비페놀-4-일-메틸)-2-피롤리돈은 산성촉매의 작용하에서 에탄올중에서 고리열기 및 에스테르화 반응에 의해, (2R,4S)-2-메틸-4-아미노-5-(1,1'-비페놀-4-일)-발레르산에틸을 얻으며, 상기 (2R,4S)-2-메틸-4-아미노-5-(1,1'-비페놀-4-일)-발레르산에틸과 호박산무수물은 알칼리성 촉진제의 작용하에서, 아미드화 반응을 일으켜 사큐비톨(Sacubitril)이 얻어지는 단계를 포함하는 하는 사큐비톨의 제조방법.
Figure 112017081076857-pct00006

(7aR, 9R, 12S) -9-methyl-10-naphthalenol was obtained by cyclization of (S) -1- 12-phenyl-7a, 8,9,10-tetrahydro-12H-naphtho [1,2-e] pyrrole [2,1- b] [1,3] 1,2-e] pyrrolo [2,1-b] pyridin-2-ylmethoxy) -7a, 8,9,10-tetrahydro- [1, 3] oxazine was synthesized by the reaction of (1S, 3R (3,3'-biphenyl-4-methyl) , 5S) -1- [[3-methyl-5- (1,1'-biphenyl-4-yl-methyl) -2- pyrrolidone] benzyl] -2- naphthalenol, 2-pyrrolidone] benzyl] -2-naphthalenol was prepared from benzyl 2- (3-methyl-5- (3R, 5S) -3-methyl-5- (1,1'-biphenol-4-yl-methyl) -2- pyrrolidone, Methyl-5- (1,1'-biphenol-4-yl-methyl) -2-pyrrolidone is hydrolyzed and esterified in ethanol under the action of an acidic catalyst (2R, 4S) -2-methyl-4-amino-5- (1,1'-biphenol-4-yl) -4-amino-5- (1,1'-biphenol-4-yl) -valerate and succinic anhydride undergo the action of an amidation reaction under the action of an alkaline promoter to obtain sacubitril By weight.
청구항 1에 있어서,
상기 (S)-1-(α-아미노벤질)-2-나프탈레놀과 2R-메틸-4-옥소-부탄산의 고리화반응의 원료투여 몰비는 1:1~2, 상기 고리화반응의 용매는 톨루엔, 1,2-디클로로 에탄, N,N-디메틸포름아미드, 아세토니트릴 또는 디메틸설폭시드, 상기 고리화반응 온도는 25~100℃로 하는 사큐비톨의 제조방법.
The method according to claim 1,
The starting molar ratio of the (S) -1- (α-aminobenzyl) -2-naphthalenol to the 2R-methyl-4-oxo-butanoic acid in the cyclization reaction is 1: 1 to 2, Wherein the solvent is toluene, 1,2-dichloroethane, N, N-dimethylformamide, acetonitrile or dimethylsulfoxide, and the cyclization temperature is 25 to 100 占 폚.
청구항 1에 있어서,
상기 (7aR,9R,12S)-9-메틸-10-옥소-12-페닐-7a,8,9,10-테트라히드로-12H-나프토[1,2-e]피롤환[2,1-b][1,3]옥사진과 (1,1'-비페닐-4-메틸) 염화 마그네슘 또는 (1,1'-비페닐-4-메틸) 브롬화 마그네슘과의 첨가반응의 원료투여 몰비는 1:1~2이고, 상기 첨가반응의 용매는 에틸에테르, 이소프로필에테르, 테트라히드로푸란 또는 2-메틸테트라히드로푸란이며, 상기 첨가반응의 온도는 -100~0℃인 사큐비톨의 제조방법.
The method according to claim 1,
(7aR, 9R, 12S) -9-methyl-10-oxo-12-phenyl-7a, 8,9,10-tetrahydro- 12H-naphtho [ (1, 1'-biphenyl-4-methyl) magnesium chloride or (1,1'-biphenyl-4-methyl) 1: 1 to 2, and the solvent for the addition reaction is ethyl ether, isopropyl ether, tetrahydrofuran or 2-methyltetrahydrofuran, and the temperature for the addition reaction is -100 to 0 ° C .
청구항 1에 있어서,
상기 탈벤젠반응의 반응 체계는 Pd/C 촉매 수소첨가 환원체계 또는 세륨함유 질산 암모늄 산화 체계이고, 상기 Pd/C 촉매 수소첨가 환원체계의 용매는 메탄올, 에탄올, 이소 프로판올, 디클로로메탄, 초산에틸 또는 이소 프로필 아세테이트로서, 상기 세륨함유 질산 암모늄 산화체계의 용매는 아세토니트릴/물, 디클로로 메탄/물 또는 테트라히드로푸란/물이며, 그 체적비는 1~5:1인 사큐비톨의 제조방법.
The method according to claim 1,
Wherein the reaction system of the debenzene reaction is a Pd / C catalytic hydrogenation reduction system or a cerium ammonium nitrate oxidation system, and the solvent of the Pd / C catalytic hydrogenation reduction system is methanol, ethanol, isopropanol, dichloromethane, Wherein the solvent of the cerium containing ammonium nitrate oxidation system is acetonitrile / water, dichloromethane / water or tetrahydrofuran / water, and the volume ratio is 1 to 5: 1.
청구항 1에 있어서,
상기 고리열기 및 에스테르화 반응의 산성촉매는 염산, 유산, 트리플루오로아세트산, 과염소산 또는 p-술폰산 톨루엔이며, 상기 고리열기 및 에스테르화 반응의 온도는 0~100℃인 사큐비톨의 제조방법.
The method according to claim 1,
Wherein the acidic catalyst of the cyclization and esterification reaction is hydrochloric acid, sulfuric acid, trifluoroacetic acid, perchloric acid or p-sulfonic acid toluene, and the temperature of the cyclic thermal and esterification reaction is 0 to 100 ° C.
청구항 1에 있어서,
상기 아미드화 반응의 알칼리 촉진제는 수산화마트륨, 탄산칼륨, 탄산나트륨, tert-부틸알코올, 피리딘 또는 트리에틸아민이고, 상기 아미드화 반응의 용매는 디클로로메탄, 테트라히드로푸란, 아세토니트릴, N,N-디메틸포름아미드 또는 디옥산이며, 상기 아미드화 반응 온도는 0~90℃인 사큐비톨의 제조방법.
The method according to claim 1,
The solvent for the amidation reaction may be dichloromethane, tetrahydrofuran, acetonitrile, N, N-dimethylformamide, N, N-dimethylacetamide, Dimethylformamide or dioxane, and the amidation reaction temperature is 0 to 90 ° C.
KR1020177023388A 2015-01-26 2016-01-04 Preparation method of sacylitol KR101961897B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510039610.7 2015-01-26
CN201510039610.7A CN104557600B (en) 2015-01-26 2015-01-26 Sha Ku is than bent preparation method
PCT/CN2016/070020 WO2016119574A1 (en) 2015-01-26 2016-01-04 Method for preparing sacubitril

Publications (2)

Publication Number Publication Date
KR20170117091A KR20170117091A (en) 2017-10-20
KR101961897B1 true KR101961897B1 (en) 2019-03-25

Family

ID=53074779

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177023388A KR101961897B1 (en) 2015-01-26 2016-01-04 Preparation method of sacylitol

Country Status (3)

Country Link
KR (1) KR101961897B1 (en)
CN (1) CN104557600B (en)
WO (1) WO2016119574A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104557600B (en) * 2015-01-26 2016-05-04 苏州明锐医药科技有限公司 Sha Ku is than bent preparation method
US10233144B2 (en) 2015-03-20 2019-03-19 Crystal Pharmatech Co., Ltd. Crystalline form of AHU377, preparation method and use thereof
CN106187808A (en) * 2015-05-08 2016-12-07 苏州鹏旭医药科技有限公司 The preparation method of AHU-377, AHU-377 intermediate and the preparation method of AHU-377 intermediate
CN104860894B (en) * 2015-06-10 2017-05-17 北京博全健医药科技有限公司 Method for preparing cardiotonic drug LCZ696
CN106309388A (en) * 2015-06-30 2017-01-11 深圳信立泰药业股份有限公司 Medicine composition for treating congestive heart failure and preparation method thereof
CN105085322B (en) * 2015-08-15 2017-10-03 浙江永宁药业股份有限公司 The Preparation Method And Their Intermediate of the intermediates of AHU 377 and the preparation method of intermediate
CN105168205A (en) * 2015-08-18 2015-12-23 泰力特医药(湖北)有限公司 Preparation method for dual inhibitor LCZ696 of angiotensin II receptor and neprilysin
CN105237560B (en) * 2015-10-15 2018-07-06 上海博氏医药科技有限公司 A kind of LZC696 intermediates and its synthetic method
CN106854187B (en) * 2015-12-08 2020-04-14 苏州晶云药物科技股份有限公司 Preparation method of AHU-377 and valsartan trisodium salt eutectic hydrate crystal form II
KR20180093984A (en) * 2015-12-10 2018-08-22 노파르티스 아게 New methods and intermediates
CN106977415B (en) * 2016-01-15 2021-03-26 广东东阳光药业有限公司 Intermediate of shakubiqu and preparation method thereof
CN109071407A (en) 2016-02-29 2018-12-21 广东东阳光药业有限公司 One seed sand library must be bent intermediate and preparation method thereof
CN105753733B (en) * 2016-04-15 2019-06-18 苏州晶云药物科技股份有限公司 Crystal form of AHU377 and preparation method thereof and purposes
JP6944473B2 (en) 2016-07-05 2021-10-06 ノバルティス アーゲー A new method for early sacubitril intermediates
CN107602399B (en) * 2016-07-11 2020-09-25 江西东邦药业有限公司 Preparation method of enkephalinase inhibitor intermediate
WO2018033866A1 (en) 2016-08-17 2018-02-22 Novartis Ag New processes and intermediates for nep inhibitor synthesis
CN106380421B (en) * 2016-08-26 2017-12-08 中国科学院上海有机化学研究所 Synthetic method bent Sha Kubi
CN108203396B (en) * 2016-12-19 2020-12-08 江西东邦药业有限公司 Synthesis of enkephalinase inhibitor
US10774036B2 (en) 2016-12-23 2020-09-15 Novartis Ag Process for early sacubitril intermediates
CN108238981A (en) * 2016-12-23 2018-07-03 宁波爱诺医药科技有限公司 A kind of preparation method of LCZ-696 key intermediates
CN106699604B (en) * 2017-01-09 2019-01-01 四川同晟生物医药有限公司 One seed sand library is than bent and its intermediate preparation method
CN106966926B (en) * 2017-04-01 2018-10-19 沧州那瑞化学科技有限公司 A kind of preparation method of LCZ696 intermediates
CN110878039A (en) * 2019-12-18 2020-03-13 株洲千金药业股份有限公司 Preparation method of Sacubitril valsartan sodium impurity
CN113121342B (en) * 2019-12-31 2022-05-31 浙江医药股份有限公司新昌制药厂 Preparation method and application of shakubiqu intermediate

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008031567A1 (en) 2006-09-13 2008-03-20 Novartis Ag Process for preparing biaryl substituted 4-amino-butyric acid or derivatives thereof and their use in the production of nep inhibitors
WO2010136474A2 (en) 2009-05-28 2010-12-02 Novartis Ag Substituted aminobutyric derivatives as neprilysin inhibitors
WO2012065956A1 (en) 2010-11-16 2012-05-24 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as nep inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217996A (en) * 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
NZ577910A (en) * 2007-01-12 2012-04-27 Novartis Ag Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid
BRPI1011657A2 (en) * 2009-05-28 2019-04-16 Novartis Ag substituted aminopropionic derivatives as neprilysin inhibitors
US8993631B2 (en) * 2010-11-16 2015-03-31 Novartis Ag Method of treating contrast-induced nephropathy
CN104230865B (en) * 2013-06-13 2018-01-09 上海翰森生物医药科技有限公司 4 amino butyric acid derivatives of biaryl substituted and its production and use
CN104557600B (en) * 2015-01-26 2016-05-04 苏州明锐医药科技有限公司 Sha Ku is than bent preparation method

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008031567A1 (en) 2006-09-13 2008-03-20 Novartis Ag Process for preparing biaryl substituted 4-amino-butyric acid or derivatives thereof and their use in the production of nep inhibitors
WO2010136474A2 (en) 2009-05-28 2010-12-02 Novartis Ag Substituted aminobutyric derivatives as neprilysin inhibitors
WO2012065956A1 (en) 2010-11-16 2012-05-24 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as nep inhibitors

Also Published As

Publication number Publication date
KR20170117091A (en) 2017-10-20
CN104557600A (en) 2015-04-29
WO2016119574A1 (en) 2016-08-04
CN104557600B (en) 2016-05-04

Similar Documents

Publication Publication Date Title
KR101961897B1 (en) Preparation method of sacylitol
JP6872500B2 (en) How to make bribalacetam
EA019431B1 (en) Process and intermediates for preparing integrase inhibitors
JP2018519280A (en) Method for preparing {1- (ethylsulfonyl) -3- [4- (7H-pyrrolo [2,3-d] pyrimidin-4-yl) -1H-pyrazol-1-yl] azetidin-3-yl} acetonitrile and Intermediate
CA2919317A1 (en) Synthesis of biphenylalaninol via novel intermediates
CN103080088B (en) Production method of intermediate compound for synthesizing medicament
EP3256444B1 (en) Process and intermediates for the preparation of nep inhibitors
JPH03294264A (en) Production of optically active 3-hydroxypyrrolidine derivative
EP2914574A2 (en) New process
JP5724119B2 (en) Process for producing tetrahydropyran-4-one and pyran-4-one
JP2020526504A (en) Substituted quinolinyl cyclohexylpropanamide compound and improved method for its production
CN113024489A (en) Preparation method of oseltamivir synthesis process impurity
CN112645863B (en) Dipyrromethene-1-ketone compound and preparation method thereof
KR100915551B1 (en) Process for the efficient preparation of 3-hydroxy pyrrolidine and derivatives thereof
JP7167171B2 (en) Method for producing tetracyclic compound
CN111349007B (en) Preparation method of (R) -4-propyl-dihydrofuran-2-ketone and preparation intermediate thereof
Lee et al. Facile One-Pot Two-Step Hydroxylation of Alkyl Halides and Alkyl Sulfonates via Acetate Intermediates
CN113024486A (en) Method for preparing oseltamivir intermediate
CN113717178B (en) Intermediate of SHP2 inhibitor and preparation method thereof
CN104981456B (en) The manufacture method of desmosine, isodensmosine and their derivative
JP7427242B2 (en) Optically active azide ester and method for producing the same
TWI551592B (en) Preparation of 3,5-dioxo hexanoate ester in two steps
KR101032761B1 (en) A method for preparing docetaxel and new intermediates for preparing the same
KR101009467B1 (en) Taxan derivative useful for synthesizing docetaxel and a method for preparing the same
JP2007070270A (en) Manufacturing method of 3-aminomethyloxetane compound

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant